Back to results
US 2022/0016247 A1Published application
Dry powder inhalation formulation and its use for the therapeutic treatment of lungs
AssigneeUniversite Libre de Bruxelles
InventorsKarim Amighi, Nathalie Wauthoz, Rémi Rosière
Life of this patent
Estimating the term…
Abstract
A dry powder inhalation formulation includes at least one active pharmaceutical ingredient (API) and a lipid matrix having at least one triglyceride chosen in the group consisting of monohydroxystearin, dihydroxystearin, trihydroxystearin and their mixture and its manufacturing method.
Claims23
A dry powder inhalation formulation comprising at least one active pharmaceutical ingredient (API) and a lipid matrix comprising at least one triglyceride chosen in the group consisting of monohydroxystearin, dihydroxystearin, trihydroxystearin, and their mixture.
Dependencies are inferred from the claim text.